Douglas Taylor Falk
Fondateur chez Vita Therapeutics, Inc.
Profil
Douglas Taylor Falk is the founder and currently serves as the Chief Executive Officer & Director of Vita Therapeutics, Inc. which is founded in 2019.
He previously worked as an Equity Research Specialist at Brown Advisory LLC from 2015 to 2019.
Falk received his undergraduate degree from Goucher College in 2014.
Postes actifs de Douglas Taylor Falk
| Sociétés | Poste | Début |
|---|---|---|
Vita Therapeutics, Inc.
 Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Fondateur | 01/01/2019 |
Anciens postes connus de Douglas Taylor Falk
| Sociétés | Poste | Fin |
|---|---|---|
Brown Advisory LLC
 Brown Advisory LLC Investment ManagersFinance Brown Advisory LLC is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm is a subsidiary of Brown Advisory Management LLC and their ultimate parent is Brown Advisory, Inc. The firm was founded and launched in 1993 as an investment management division of Alex. Brown & Sons, a Baltimore-based investment bank founded in 1800. In 1998, they became independently owned through an employee-led buyout. Brown Advisory provides investment management services to individuals and institutions. | Analyst-Equity | 01/01/2019 |
Formation de Douglas Taylor Falk
| Goucher College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Brown Advisory LLC
Brown Advisory LLC Investment ManagersFinance Brown Advisory LLC is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm is a subsidiary of Brown Advisory Management LLC and their ultimate parent is Brown Advisory, Inc. The firm was founded and launched in 1993 as an investment management division of Alex. Brown & Sons, a Baltimore-based investment bank founded in 1800. In 1998, they became independently owned through an employee-led buyout. Brown Advisory provides investment management services to individuals and institutions. | Finance |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
